ImmuPharma (LON:IMM) Shares Up 148.4% – Time to Buy?

ImmuPharma plc (LON:IMM)’s share price rose 148.4% during trading on Monday . The company traded as high as GBX 6.90 ($0.09) and last traded at GBX 5.80 ($0.08). Approximately 88,450,148 shares changed hands during trading, an increase of 1,257% from the average daily volume of 6,519,289 shares. The stock had previously closed at GBX 2.34 ($0.03).

ImmuPharma Price Performance

The stock has a market capitalization of £24.15 million, a PE ratio of -966.67 and a beta of 1.53. The business has a 50 day moving average price of GBX 1.99 and a 200 day moving average price of GBX 2.65.

ImmuPharma (LON:IMM) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.